Global Artificial Blood Market Size, Status and Forecast 2019-2025

2 Global Artificial Blood Quarterly Market Size Analysis

• 2.1 Artificial Blood Business Impact Assessment - COVID-19
  • 2.1.1 Global Artificial Blood Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Artificial Blood Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global Artificial Blood Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, Artificial Blood Headquarters and Area Served
• 3.3 Date of Key Players Enter into Artificial Blood Market
• 3.4 Key Players Artificial Blood Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Artificial Blood Segments, By Type

• 4.1 Introduction
  • 1.4.1 Human Blood
  • 1.4.2 Synthetic Blood
  • 1.4.3 Animal Blood
• 4.2 By Type, Global Artificial Blood Market Size, 2019-2021

5 Impact of Covid-19 on Artificial Blood Segments, By Application

• 5.1 Overview
  • 5.5.1 Hemoglobin-Based Oxygen Carriers (HBOCs)
  • 5.5.2 Perflurocarbon Emulsions (PFCEs)
• 5.2 By Application, Global Artificial Blood Market Size, 2019-2021
  • 5.2.1 By Application, Global Artificial Blood Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Dextro-Sang Corporation
  • 7.1.1 Dextro-Sang Corporation Business Overview
  • 7.1.2 Dextro-Sang Corporation Artificial Blood Quarterly Revenue, 2020
  • 7.1.3 Dextro-Sang Corporation Artificial Blood Product Introduction
  • 7.1.4 Dextro-Sang Corporation Response to COVID-19 and Related Developments
• 7.2 BioPure Corporation
  • 7.2.1 BioPure Corporation Business Overview
  • 7.2.2 BioPure Corporation Artificial Blood Quarterly Revenue, 2020
  • 7.2.3 BioPure Corporation Artificial Blood Product Introduction
  • 7.2.4 BioPure Corporation Response to COVID-19 and Related Developments
• 7.3 Sangart
  • 7.3.1 Sangart Business Overview
  • 7.3.2 Sangart Artificial Blood Quarterly Revenue, 2020
  • 7.3.3 Sangart Artificial Blood Product Introduction
  • 7.3.4 Sangart Response to COVID-19 and Related Developments
• 7.4 Northfield Laboratories
  • 7.4.1 Northfield Laboratories Business Overview
  • 7.4.2 Northfield Laboratories Artificial Blood Quarterly Revenue, 2020
  • 7.4.3 Northfield Laboratories Artificial Blood Product Introduction
  • 7.4.4 Northfield Laboratories Response to COVID-19 and Related Developments
• 7.5 Baxter International
  • 7.5.1 Baxter International Business Overview
  • 7.5.2 Baxter International Artificial Blood Quarterly Revenue, 2020
  • 7.5.3 Baxter International Artificial Blood Product Introduction
  • 7.5.4 Baxter International Response to COVID-19 and Related Developments
• 7.6 Dentritech
  • 7.6.1 Dentritech Business Overview
  • 7.6.2 Dentritech Artificial Blood Quarterly Revenue, 2020
  • 7.6.3 Dentritech Artificial Blood Product Introduction
  • 7.6.4 Dentritech Response to COVID-19 and Related Developments
• 7.7 FluorO2 Therapeutics
  • 7.7.1 FluorO2 Therapeutics Business Overview
  • 7.7.2 FluorO2 Therapeutics Artificial Blood Quarterly Revenue, 2020
  • 7.7.3 FluorO2 Therapeutics Artificial Blood Product Introduction
  • 7.7.4 FluorO2 Therapeutics Response to COVID-19 and Related Developments
• 7.8 Nuvox Pharma
  • 7.8.1 Nuvox Pharma Business Overview
  • 7.8.2 Nuvox Pharma Artificial Blood Quarterly Revenue, 2020
  • 7.8.3 Nuvox Pharma Artificial Blood Product Introduction
  • 7.8.4 Nuvox Pharma Response to COVID-19 and Related Developments
• 7.9 Alpha Therapeutic Corporation
  • 7.9.1 Alpha Therapeutic Corporation Business Overview
  • 7.9.2 Alpha Therapeutic Corporation Artificial Blood Quarterly Revenue, 2020
  • 7.9.3 Alpha Therapeutic Corporation Artificial Blood Product Introduction
  • 7.9.4 Alpha Therapeutic Corporation Response to COVID-19 and Related Developments
• 7.10 HemoBioTech
  • 7.10.1 HemoBioTech Business Overview
  • 7.10.2 HemoBioTech Artificial Blood Quarterly Revenue, 2020
  • 7.10.3 HemoBioTech Artificial Blood Product Introduction
  • 7.10.4 HemoBioTech Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US